Evergreen Capital Management LLC Sells 868 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Evergreen Capital Management LLC lessened its position in iShares Biotechnology ETF (NASDAQ:IBB) by 2.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,734 shares of the financial services provider’s stock after selling 868 shares during the period. Evergreen Capital Management LLC owned about 0.06% of iShares Biotechnology ETF worth $4,768,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new stake in iShares Biotechnology ETF in the 1st quarter valued at $27,000. Bbjs Financial Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the second quarter valued at about $31,000. Pacifica Partners Inc. lifted its stake in shares of iShares Biotechnology ETF by 118.2% during the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after buying an additional 130 shares during the last quarter. YHB Investment Advisors Inc. bought a new stake in shares of iShares Biotechnology ETF during the 1st quarter worth about $37,000. Finally, Mather Group LLC. bought a new stake in shares of iShares Biotechnology ETF during the 1st quarter worth about $57,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $145.58 on Tuesday. The company’s 50-day moving average price is $145.81 and its two-hundred day moving average price is $138.68. iShares Biotechnology ETF has a twelve month low of $111.83 and a twelve month high of $150.57.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.